FOR INVASIVE INFECTIONS
SUCH As SEPSIS
How HelixBind is Changing Care
Revolutionizing CARE
HelixBind is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis.
Its novel platform provides faster, more accurate, and more informative microbiology results, assisting clinicians in precisely identifying bloodstream infections and developing personalized antimicrobial interventions for infected patients.
Our approach can improve outcomes, save lives, and reduce the spread of antimicrobial resistance.
HelixBind in the News
RAPID & ACCURATE IDENTIFICATION
HelixBind is growing and actively looking for talented individuals.
CAREERS at helix bind
Explore HelixBind Technology
SUPPORTING BETTER OUTCOMES
The Challenge of Sepsis
Sepsis, caused by a severe immune response to a bloodstream infection, is a major global health crisis.
Every year in the US, there are 1.7M cases, and more than 270,000 of those patients will not survive. Globally the situation is more dire, with 30M annual cases leading to well over 6M deaths.
Prognosis for septic patients deteriorates hourly. Fast and accurate identification and characterization of the infection is crucial so physicians can initiate the appropriate antimicrobial treatment as soon as possible.
identify the infection faster
HELIXBIND
RESULTS IN 3 HOURS
Traditional blood culture test
RESULTS IN 2-3 DAYS
HelixBind results may help guide appropriate clinical decisions and select the best treatment options long before culture results become available.
CONTACT HELIXBIND
HelixBind, Inc.
1300 Massachusetts Avenue, Unit 103
Boxborough, MA 01719
For general inquiries, contact us at:
info@helixbind.com
774-300-8557
For partnerships and business development:
bd@helixbind.com
For press: